Cronos Q3 2026: Revenue Up 75% to $63.5M, Adjusted EBITDA $17.1M, Buybacks Cut Share Count
CRON sits 58% above its 52-week low of $2.28 on elevated volume (2.0× avg).
Summary
Cronos posted record Q3 2026 net revenue of $63.5M (up 75%), gross profit of $32.3M and Adjusted EBITDA of $17.1M, while repurchasing 3.2M shares for $9.4M and holding $840.6M in cash and investments.
Key Events · Earnings and Guidance · CRON
-
Record Q3 Revenue, Up 75%
Net revenue was $63.5M versus $36.3M a year ago, a 73% increase on a constant-currency basis; Canada contributed $35.1M, Israel $15.1M and other countries $13.2M (up 614%).
-
Adjusted EBITDA More Than Tripled
Adjusted EBITDA reached $17.1M, up $11.4M or 201% from $5.7M, on gross profit of $32.3M at a 50.9% margin.
-
Net Income Fell on Prior-Year FX Gain
GAAP net income was $17.8M versus $28.3M, as the prior-year quarter included a $19.8M foreign currency gain that did not recur.
-
Buybacks Shrink Share Count
Cronos repurchased 3.2M shares for $9.4M in Q3 and 15.5M shares for $42.3M over nine months; shares outstanding fell to 367.5M from 381.6M at December 31, 2025.
Analysis · CRON · Life Sciences
For the second consecutive quarter, Cronos set records for net revenue, gross profit and Adjusted EBITDA—and did so while shrinking the share count rather than diluting. Revenue of $63.5M rose 75% year over year (73% on a constant-currency, organic basis), gross margin held at 50.9%, and Adjusted EBITDA of $17.1M was up 201% from $5.7M a year ago. The one soft spot is GAAP net income, which fell to $17.8M from $28.3M because last year's quarter carried a $19.8M foreign-currency gain that did not repeat. Cash generation is real: $69.2M of operating cash flow over nine months funded $42.3M of buybacks and still left $840.6M in cash, deposits and short-term investments. The CanAdelaar deal closed October 15, 2026, giving Cronos a position in the Netherlands' adult-use pilot, but integration and the Dutch program's regulatory risk are now part of the story.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CRON was trading at $3.60 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.3B. The 52-week trading range was $2.28 to $3.61. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.